A Comparison Between Child-Pugh and Albumin-Bilirubin Scores
1 other identifier
observational
230
0 countries
N/A
Brief Summary
To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2005
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
May 12, 2018
CompletedFirst Posted
Study publicly available on registry
May 23, 2018
CompletedMay 29, 2018
May 1, 2018
10.6 years
May 12, 2018
May 24, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival of all patients
Overall survival of all patients among different Child-Pugh and albumin-bilirubin scores
5 years
Secondary Outcomes (3)
Short-term mortality of all patients
Ninety days
Short-term mortality of surgical subgroup
Ninety days
Short-term mortality of non-surgical subgroup
Ninety days
Study Arms (2)
Surgical treatment
Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
Non-surgical treatment
Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
Interventions
Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
Eligibility Criteria
From January 2005 to August 2015, all patients complied with the criteria mentioned above who received surgical treatment or non-surgical treatment at the investigator's center were included in this study.
You may qualify if:
- Be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed by Intraperitoneal exploration or clinical signs and symptoms in combination with imaging examination.
You may not qualify if:
- Be diagnosed as not hepatocellular carcinoma pathologically；had repeated transcatheter arterial chemoembolization(TACE) or a long history (more than 1 year) of cancer treatment; loss of follow up or without complete data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Wu JJ, Zhang ZG, Zhu P, Mba'nbo-Koumpa AA, Zhang BX, Chen XP, Shu C, Zhang WG, Feng RJ, Li GX. Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience. Asian J Surg. 2019 Sep;42(9):874-882. doi: 10.1016/j.asjsur.2018.12.015. Epub 2019 Jan 28.
PMID: 30704966DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Xiao-ping Chen, Prof. PHD
Huazhong University of Science and Technology
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 12, 2018
First Posted
May 23, 2018
Study Start
January 1, 2005
Primary Completion
August 1, 2015
Study Completion
January 1, 2018
Last Updated
May 29, 2018
Record last verified: 2018-05